Live Breaking News & Updates on Her3 Positive Circulating Tumor Cell Count

Stay updated with breaking news from Her3 positive circulating tumor cell count. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer. ....

France General , Gustave Roussy , Barbara Pistilli , Breast Cancer Annual Congress , Cancer Annual , Breast Cancer , The 2023 Esmo Breast Cancer Annual Congress , Phase 2 Icarus Breast01 Trial Nct04965766 , Patritumab Deruxtecan , Her3 Positive Circulating Tumor Cell Count ,